Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix

Journal of Clinical Oncology

Volumn 16, Issue 3, 1998, Pages 1094-1098

  Morris, Mitchell ^a   Brader, Kevin R ^a   Levenback, Charles ^a   Burke, Thomas W ^a   Atkinson, E Neely ^a   Scott, Wanza R ^a   Gershenson, David M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NAVELBINE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN TISSUE; NEUROTOXICITY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; UTERINE CERVIX CANCER; WORLD HEALTH ORGANIZATION;

EID: 0031909627     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.3.1094     Document Type: Article

References (29)

1. Omura GA: Chemotherapy for cervix cancer. Semin Oncol 21:54-62, 1994
2. Park RC, Thigpen JT: Chemotherapy in advanced and recurrent cervical cancer. Cancer 71:1446-1450, 1993
3. Alberts DA, Garcia D, Mason-Liddil N: Cisplatin in advanced cancer of the cervix: An update. Semin Oncol 18:11-24, 1991
4. Canobbio L, Boccardo F, Pastorino G, et al: Phase II study of vinorelbine in advanced breast cancer. Semin Oncol 16:33-36, 1989
5. Bajetta E, Di Leo A, Biganzoli L, et al: Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: Activity in platinum-resistant disease. J Clin Oncol 14:2546-2551, 1996
6. Murphy BA: New drug therapy for squamous cell carcinoma of the head and neck. Curr Opin Oncol 8:221-226, 1996
7. Viallet J, Ayoub J, Rousseau P, et al: Navelbine (vinorelbine) in the adjuvant and neoadjuvant treatment of non-small-cell lung cancer. Semin Oncol 21:64-72, 1994
8. Fellous A, Ohayon R, Vacassin T, et al: Biochemical effects of vinorelbine on tubulin and associated proteins. Semin Oncol 16:2-4, 1989
9. WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication no. 28, Geneva, Switzerland, World Health Organization, 1979
10. Blessing JA: Design, analysis, and interpretation of chemotherapy trials in gynecologic cancer, in Deppe G (ed): Chemotherapy of Gynecologic Cancer, New York, NY, Liss, 1984, pp 49-83
11. Simon R: Optimal two-stage designs for phase II clincial trials. Control Clin Trials 10:1-10, 1989
12. Kaplan E, Meier F: Nonparametric estimation from incomplete observations. J Am Stat Assoc 58:457-481, 1958
13. Shingleton HM, Soong SJ, Gelder MS, et al: Clinical and histopathologic factors predicting recurrence and survival after pelvic exenteration for cancer of the cervix. Obstet Gynecol 73:1027-1034, 1989
14. Depierre A, Lemarie E, Dabouis G, et al: A phase II trial of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol 14:115-119, 1991
15. Yokoyama A, Furuse K, Niitani H, et al: Multiinstitutional phase II study of Navelbine (vinorelbine) in non-small-cell lung cancer. Proc Am Soc Clin Oncol 11:287, 1992 (abstr)
16. Crivellari D, Veronesi A, Sacco C, et al: Phase II study of vinorelbine (v) in 50 patients (pts) with non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 13:355, 1994 (abstr)
17. Depierre A, Chastang C, Quiox E, et al: Vinorelbine versus vinorelbine plus cisplatin in advanced non-small-cell lung cancer: A randomized trial. Ann Oncol 5:37-42, 1994
18. Le Chevalier T, Brisgard D, Douillard J, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367, 1994
19. Crawford J, O'Rourke M, Schiller JH, et al: Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. J Clin Oncol 14:2774-2784, 1996
20. Vallejo C, Romero A, Perez J, et al: Ifosfamide and vinorelbine as first-line chemotherapy for advanced non-small-cell lung carcinoma. Am J Clin Oncol 19:584-588, 1996
21. Chang AY, DeVore R, Johnson D: Pilot study of Navelbine (vinorelbine) and paclitaxel in patients with refractory non- small-cell lung cancer. Semin Oncol 23:19-21, 1996
22. Testolin A, Recher G, Cristoferi V, et al: Vinorelbine in pretreated advanced head and neck squamous cell carcinoma. Invest New Drugs 12:231-234, 1994
23. Conroy T, Etienne P, Adenis A, et al: Phase II trial of vinorelbine in metastatic squamous cell carcinoma of the esophagus. J Clin Oncol 14:164-170, 1996
24. Gebbia V, Testa A, Valenza R, et al: A pilot study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer 29A:1358-1359, 1993
25. Gebbia V, Testa A, Di Gregorio C, et al: Vinorelbine plus cisplatin in recurrent or previously untreated unresectable squamous cell carcinoma of the head and neck. Am J Clin Oncol 18:293-296, 1995
26. Gebbia V, Mantovani G, Farris A, et al: Vinorelbine, cisplatin, and 5-fluorouracil as initial treatment for previously untreated, unresectable squamous cell carcinoma of the head and neck. Cancer 79:1394-1400, 1997
27. Lacava JA, Leone BA, Machiavelli M, et al: Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma. J Clin Oncol 15:604-609, 1997
28. Potter ME, Hatch KD, Potter MY, et al: Factors affecting response of recurrent squamous cell carcinoma of the cervix to cisplatin. Cancer 63:1283-1286, 1989
29. Zanetta G, Torri W, Bocciolone L, et al: Factors predicting response to chemotherapy and survival in patients with metastatic or recurrent squamous cell cervical carcinoma: A multivariate analysis. Gynecol Oncol 58:58-63, 1995